AUS
NZ
UK
CA
USA
IND
Highlights:
Baird upgraded McKesson Corporation’s stock from Neutral to Outperform, raising its price target to $688 from $531.
McKesson's strong performance in the U.S. Pharmaceutical Distribution and Prescription Technology Solutions sectors drive a positive outlook.
The company has made significant strategic moves, including acquisitions and contract wins, which are expected to support growth in the coming years.
McKesson Corporation (NYSE:MCK) received an upgrade from Baird, which raised its rating from Neutral to Outperform and significantly increased its price target to $688, up from $531. This change reflects the company's strong performance in key areas, particularly its U.S. Pharmaceutical Distribution and Prescription Technology Solutions segments.
The U.S. Pharmaceutical Distribution sector, which accounts for around 90% of McKesson's total revenue, has been seeing solid demand for branded and specialty products. The company’s expansion into oncology and biopharma services further strengthens its position. Additionally, the sector is poised to benefit from a steady flow of new generics and biosimilars, which will likely boost growth through the end of the decade. McKesson's recent contract win with OptumRx is expected to enhance performance in this segment starting in fiscal Q2 2025 and continue into the following years.
The Prescription Technology Solutions business is also gaining traction, as there is increasing demand for solutions that improve access to medications, support treatment adherence, and manage affordability challenges, especially in the area of prior authorizations.
Internationally, McKesson has completed several divestitures, including the sale of its Canadian retail pharmacy and wellness assets. While the company has wound down its COVID-related operations in the Medical-Surgical segment, there has been some short-term performance impact due to weakness in the Primary Care market, necessitating restructuring efforts.
In its latest financial results, McKesson reported a strong first-quarter performance for fiscal 2025, with revenues rising by 6% year-over-year. Adjusted earnings also saw growth, and the company announced a 15% increase in its quarterly dividend alongside an additional $4 billion for share repurchases. Recent acquisitions, such as Florida Cancer Specialists and a controlling stake in Core Ventures, further solidify McKesson's position in the healthcare sector, particularly in oncology.
McKesson's solid fundamentals and strategic moves, coupled with a positive outlook for its core businesses, position the company for continued growth.
